Celcuity (CELC): Fresh Phase 3 Breast Cancer Data Prompts Closer Look at Gedatolisib-Driven Valuation [Yahoo! Finance]
Celcuity Inc. (CELC)
Last celcuity inc. earnings: 3/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
celcuity.com/home/investors
Company Research
Source: Yahoo! Finance
See our latest analysis for Celcuity. The latest VIKTORIA-1 update lands after an explosive run, with Celcuity's 90 day share price return of around 84% and 1 year total shareholder return close to 700%, signaling strong, momentum driven optimism around gedatolisib's potential. If Celcuity's surge has you thinking about what else could rerate on major trial readouts, it is worth exploring other innovative healthcare stocks that might be earlier in their story. With the stock up nearly sevenfold in a year but still trading below both intrinsic value estimates and the Street's target, are investors staring at rare upside in Celcuity, or has the market already priced in gedatolisib's next leg of growth? Celcuity's latest close at $100.39 comes alongside a steep 39.7x price to book ratio, signalling a market that is paying up relative to assets. Price to book compares the company's market value to its net assets, and for early stage biotechs like Celcuity, it often reflects exp
Show less
Read more
Impact Snapshot
Event Time:
CELC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELC alerts
High impacting Celcuity Inc. news events
Weekly update
A roundup of the hottest topics
CELC
News
- How Investors Are Reacting To Celcuity (CELC) Gedatolisib's Phase 3 Breast Cancer Data And Safety Profile [Yahoo! Finance]Yahoo! Finance
- Celcuity (NASDAQ:CELC) was upgraded by analysts at Wells Fargo & Company to a "strong-buy" rating.MarketBeat
- Celcuity (NASDAQ:CELC) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating on the stock.MarketBeat
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium [Yahoo! Finance]Yahoo! Finance
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer SymposiumGlobeNewswire
CELC
Earnings
- 11/12/25 - Beat
CELC
Sec Filings
- 12/9/25 - Form 4
- 12/8/25 - Form 4
- 12/5/25 - Form 144
- CELC's page on the SEC website